Robert Gallotto is a co-founder and serves as President and Chief Executive Officer of Anagram Therapeutics. Mr. Gallotto is an experienced pharmaceutical executive, with a 35-year track record of building companies focused in cystic fibrosis and other rare diseases. Prior to joining Anagram, Mr. Gallotto was the co-founder and served as President of Alcresta Therapeutics, a company focused on developing products for cystic fibrosis and other rare diseases. Mr. Gallotto built the company from an idea to the successful launch of its first product, RELiZORB, a novel medical device awarded the 2016 Medical Device Design Excellence Gold Medal Award. Mr. Gallotto has been involved with several collaborations with the CF Foundation over the past 20 years and is the inventor of numerous issued patents. Mr. Gallotto also served as co-founder and Chief Operating Officer of Allena Pharmaceuticals. Prior to Alcresta and Allena, Mr. Gallotto served as Chief Business Officer of Alnara Pharmaceuticals, until the company was acquired by Eli Lilly. Mr. Gallotto also served as Vice President of strategic planning, business, and commercial development for Altus Pharmaceuticals. Before joining Altus, Mr. Gallotto served in various positions in sales and marketing, business development and product management with companies such as Biogen, Ares-Serono, Sage BioPharma and The Upjohn Company. Mr. Gallotto holds a B.S. in biology from Stonehill College.

Evan Bailey, M.D. serves as Chief Medical Officer at Anagram Therapeutics. A pediatric pulmonologist by training, Dr. Bailey has spent his career at the forefront of cystic fibrosis medicine. Dr. Bailey served as Medical Director at Vertex Pharmaceuticals, where he led the 2019 U.S. launch of TRIKAFTA® for the treatment of CF before serving as Global Medical Lead for the CF pipeline. He most recently served as Chief Medical Officer of Applied Therapeutics. Earlier in his career, Dr. Bailey was Assistant Professor of Pediatrics at the University of Massachusetts Medical School, where he was a principal investigator for multiple clinical trials running both the CF clinical and research programs. He completed his residency and fellowship training at Boston Children's Hospital and holds an MD from Loyola University Chicago Stritch School of Medicine. Dr. Bailey obtained an MA in Medical Sciences from the Boston University School of Medicine and a Bachelor of Science in Chemistry and French from Boston College.

David Brown serves as Anagram Therapeutics' Chief of Technology Development with more than twenty-five years of experience in pharmaceutical and medical device innovation and commercial manufacturing. Mr. Brown provides leadership of product and process development, program management, and supply chain. Prior to joining Anagram, Mr. Brown was Vice President of Technical Operations at Alcresta Therapeutics, Vice President of Technical Operations at Stealth Biotherapeutics, and Strategic Account Executive for Patheon. Mr. Brown earned a B.S. in chemical engineering from Northeastern University.

Tim Caffrey is Vice President of Finance at Anagram Therapeutics. He is a finance and operations executive with more than 15 years of experience in biotech and other industries, with expertise in financial strategy, FP&A, IPO readiness, reporting systems, and compliance. Tim joins Anagram from Neurogastrx, a clinical-stage biopharmaceutical company focused on gastrointestinal diseases, where he served as Vice President of Finance. Previously, he held positions of increasing responsibility at Concert Pharmaceuticals, including Director, Corporate Controller. Tim began his career in Ernst & Young's commercial audit practice and is a licensed certified public accountant in Massachusetts. He holds a Master's degree in Accounting from Bentley University's McCallum Graduate School of Business and a Juris Doctor from Northeastern University.

Marcie Clarkin, RN, BS is the Vice President of Clinical Strategic Operations and is responsible for providing strategic and operational leadership at Anagram. Previously, Ms. Clarkin served as the Senior Vice President Global Clinical Operations at uniQure where she directed and supported team delivery/strategy for on time recruitment and key data milestone delivery for the Hemophilia B gene therapy program. Her background includes leadership roles in Quality and Compliance where she developed and implemented global systems and processes while assuring compliance and strategic risk mitigation across both development and commercial products for organizations such as Visterra Inc., Radius Health Inc., Boston Scientific Corporation and AMAG Pharmaceuticals, Inc. Marcie earned her Bachelor of Science, Nursing from Cedar Crest College Allentown, PA.

Pamela Nelson serves as Executive Vice President Regulatory Affairs. Ms. Nelson brings over 28 years of experience in the biopharmaceutical industry, leading global regulatory strategies for all phases of development through commercialization across a range of therapeutic areas. Before joining Anagram Therapeutics, she served as Senior Vice President, Regulatory Affairs at Lyra Therapeutics. Previously, Ms. Nelson held regulatory positions at Avedro, Alnara Pharmaceuticals, Altus Pharmaceuticals, Alkermes and Genzyme. Ms. Nelson holds a B.A. in English and an M.Ed in education administration from the University of Massachusetts at Amherst.

Hugh Wight has been with Anagram since 2023, most recently serving as Chief of Corporate Development before his promotion to Chief Operating Officer. He brings more than 30 years of experience advancing biologic and small-molecule programs from early development through marketing authorization, with expertise in building operational frameworks that enable complex drug development. At Anagram, Hugh has been instrumental in developing a global manufacturing program for what could be the world's first orally delivered recombinant pancreatic enzyme. Prior to joining Anagram, he held roles of increasing responsibility at Allena Pharmaceuticals, Alcresta Therapeutics, Alnara Pharmaceuticals, Altus Pharmaceuticals, and Alkermes, contributing to multiple development and commercialization efforts across enzyme therapies and metabolic disease programs. Hugh received a Bachelor of Science in Microbiology from the University of Maine.